Imunon, Inc. (IMNN) Key Metrics

NASDAQ: IMNNValuation, returns, debt and efficiency ratios over 10 years.

IMNN valuation today

Trailing 12 months · as of October 17, 2026
Market cap
$5.7M
Enterprise value
$9.2M
P/E (TTM)
—
Forward P/E
16.8
PEG ratio
5.03
Price / sales
17.9
Price / book
2.0
EV / EBITDA
0.9
Dividend yield
—
Beta
2.00

IMNN key metrics, 2016–2025

Fiscal year ended December 31, 2025 · U.S. dollars

IMNN returns How much profit the business earns on the capital it uses.

Return on equity−45.2 pts
−256.4%
2025 · hover or tap a bar for each year
2016: −162.7% (−52.5 pts)2017: −122.1% (+40.6 pts)2018: −50.0% (+72.1 pts)2019: −95.2% (−45.2 pts)2020: −129.5% (−34.4 pts)2021: −55.8% (+73.7 pts)2022: −84.3% (−28.5 pts)2023: −91.4% (−7.0 pts)2024: −211.2% (−119.8 pts)2025: −256.4% (−45.2 pts)
20162025
Return on assets−14.0 pts
−131.7%
2025 · hover or tap a bar for each year
2016: −55.2% (−9.4 pts)2017: −52.1% (+3.1 pts)2018: −25.2% (+26.9 pts)2019: −39.6% (−14.4 pts)2020: −56.7% (−17.1 pts)2021: −37.2% (+19.5 pts)2022: −60.8% (−23.6 pts)2023: −59.2% (+1.6 pts)2024: −117.7% (−58.5 pts)2025: −131.7% (−14.0 pts)
20162025
Asset turnover
0.00
2025 · hover or tap a bar for each year
2016: 0.01 (+22.8%)2017: 0.01 (+1.9%)2018: 0.01 (−17.0%)2019: 0.01 (+10.8%)2020: 0.01 (+12.3%)2021: 0.01 (−32.1%)2022: 0.01 (−5.5%)2023: 0.00 (−55.2%)2024: 0.00 (−100.0%)2025: 0.00
20162025

IMNN valuation history

Fiscal year-endToday10-year median

IMNN returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

IMNN debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

IMNN cash returned to shareholders

DividendsBuybacksFree cash flow

IMNN price vs earnings per share

Share price at year-endEPS (right axis)

IMNN key metrics

2016–2025
Imunon, Inc. key metrics by fiscal year
2025202420232022202120202019201820172016
Valuation
Market capitalization$8.1M—————————
Enterprise value$315,630—————————
Price / book1.1—————————
Earnings yield−179.2%—————————
Free cash flow yield−175.3%—————————
Dividend yield0.1%—————————
Shareholder yield (dividends + buybacks)0.1%—————————
Share price at fiscal year-end$3.81$10.78$7.71$15.31$91.87$120.96$290.93$239.89$455.96$723.84
Per share
Revenue per share$0.00—————————
Earnings per share−$6.83—————————
Operating cash flow per share−$6.55—————————
Free cash flow per share−$6.68—————————
Cash per share$4.14—————————
Book value per share$3.33—————————
Tangible book value per share$3.33—————————
Dividends per share$0.00—————————
Capex per share$0.13—————————
Debt per share$0.47—————————
Shares outstanding2.1M—————————
Returns & profitability
Return on equity (ROE)−256.4%−211.2%−91.4%−84.3%−55.8%−129.5%−95.2%−50.0%−122.1%−162.7%
Return on invested capital (ROIC)———−247.8%−160.5%−156.4%−237.2%−639.7%−388.1%−278.2%
Return on assets (ROA)−131.7%−117.7%−59.2%−60.8%−37.2%−56.7%−39.6%−25.2%−52.1%−55.2%
Return on tangible assets−118.0%−191.6%−89.0%−81.6%−34.2%−97.3%−83.3%−41.6%−83.3%−433.8%
Financial health
Total debt$1.0M$1.1M$1.6M$6.3M$6.6M$6.2M$11.3M$9.4M—$2.6M
Cash & short-term investments$8.8M$5.9M$15.7M$32.7M$49.4M$17.2M$14.9M$27.6M$24.2M$4.3M
Net debt−$7.8M−$4.7M−$14.1M−$26.5M−$42.8M−$11.0M−$3.5M−$18.2M−$24.2M−$1.7M
Debt / equity0.140.270.120.210.120.330.780.45—0.38
Debt / assets0.080.120.070.140.090.170.300.20—0.08
Current ratio2.321.672.473.667.672.792.064.613.920.54
Quick ratio2.321.672.473.537.332.792.064.613.920.53
Interest coverage——-106.7-5.0-36.9-14.3-14.8-29.6-201.3-28.6
Working capital$6.1M$3.2M$10.8M$26.7M$45.2M$12.1M$8.3M$22.0M$18.1M−$3.9M
Invested capital−$711,000−$489,176−$683,297$2.8M$13.0M$7.6M$11.0M$2.7M$2.5M$5.0M
Tangible asset value$7.1M$4.2M$13.4M$29.3M$42.4M$3.2M−$3.5M$2.6M$3.7M−$19.0M
Net current asset value$5.5M$2.5M$9.7M$22.1M$33.7M−$91,385−$7.5M$2.1M$3.5M−$19.6M
Graham net-net per share$1.67—————————
Capital allocation
Dividends paid$10,277$0————————
Share buybacks (net)——$0$28.5M$0—————
Capex / revenue——361.4%53.6%62.3%3.8%69.8%27.7%7.7%12.5%
Capex / depreciation0.400.040.630.370.440.030.480.390.070.06
Stock-based compensation / revenue——607.2%534.6%751.9%370.3%457.3%920.9%221.0%302.2%
R&D / revenue——9,030.2%2,346.7%2,123.9%2,269.0%2,613.1%2,373.1%2,615.7%2,924.6%
SG&A / revenue——7,794.2%2,737.6%2,177.6%1,528.3%1,600.0%1,939.9%1,177.9%1,305.4%
Efficiency
Days sales outstanding———86.879.5—32.744.821.311.2
Days of inventory on hand———925.11,214.1—————
Days payables outstanding—1,223.71,800.11,530.11,244.282.282.2106.287.9—
Cash conversion cycle (days)———-518.149.4—-49.5-61.4-66.5—
Receivables turnover———4.214.59—11.158.1517.1132.53
Payables turnover—0.300.200.240.294.444.443.444.150.00
Inventory turnover———0.390.30————0.00
Asset turnover0.000.000.000.010.010.010.010.010.010.01
Average receivables———$118,888$108,844—$44,839$61,374$29,224$15,368
Average payables$1.3M$2.4M$3.6M$3.1M$2.4M$2.6M$2.9M$3.2M$3.1M$2.9M
Average inventory———$1.9M$2.3M————$86,978
Intangibles / total assets0.0%0.0%0.0%0.0%18.1%41.2%47.2%39.0%48.4%83.5%

Computed from IMNN's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

IMNN valuation and financial ratios

Imunon earned a return on equity of −256.4% in fiscal 2025. It ended the year with $1.0 million of debt and $8.8 million in cash and short-term investments, a net cash position of $7.8 million. It returned $0.0 million to shareholders: $0.0 million in dividends and $0 in share buybacks.

See the IMNN income statement, the IMNN chart for price history, or the IMNN stock overview for the latest quote and news.

IMNN key metrics FAQ

What is Imunon's return on equity?

Imunon's return on equity (ROE) was −256.4% in fiscal 2025: net income of -$14.5 million on average shareholders' equity of $5.7 million.

How much debt does Imunon have?

Imunon had total debt of $1.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.14 and more cash than debt.

What is Imunon's dividend yield?

Imunon paid $0.0 million in dividends in fiscal 2025 ($0.00 per share), a payout ratio of —.

What is Imunon's free cash flow yield?

Imunon generated -$14.2 million of free cash flow in fiscal 2025, a free cash flow yield of −175.3% on its market value at year-end ($8.1 million).

What is Imunon's current ratio?

Imunon's current ratio was 2.32 at the end of fiscal 2025: current assets were 2.32 times current liabilities.

Biotechnology key metrics